Intra-Cellular Therapies, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD from Q4 2012 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Intra-Cellular Therapies, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q4 2012 to Q4 2023.
  • Intra-Cellular Therapies, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending December 31, 2023 was $139M, a 17.7% decline year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $139M -$29.9M -17.7% Dec 31, 2023 10-K 2024-02-22
Q4 2022 $169M +$31M +22.6% Dec 31, 2022 10-K 2024-02-22
Q4 2021 $138M +$51.8M +60.4% Dec 31, 2021 10-K 2023-03-01
Q4 2020 $85.8M +$36.1M +72.6% Dec 31, 2020 10-K 2022-03-01
Q4 2019 $49.7M +$5.8M +13.2% Dec 31, 2019 10-K 2021-02-25
Q4 2018 $43.9M +$3.13M +7.67% Dec 31, 2018 10-K 2020-03-02
Q4 2017 $40.7M -$8.88M -17.9% Dec 31, 2017 10-K 2019-02-27
Q4 2016 $49.6M -$27.1M -35.3% Dec 31, 2016 10-K 2018-03-01
Q4 2015 $76.7M +$41.9M +120% Dec 31, 2015 10-K 2017-03-01
Q4 2014 $34.9M +$12.5M +56% Dec 31, 2014 10-K 2016-02-25
Q4 2013 $22.3M +$14M +168% Dec 31, 2013 10-K 2015-03-12
Q4 2012 $8.33M Dec 31, 2012 10-K 2014-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.